Doxycycline Hyclate
Brand names: Doxy 100, Doxycycline Hyclate, Targadox
Part of: Common antibiotics
At a glance
- Medicare prescriptions, 2024
- 5,176,266
- Medicare drug cost
- $64.1M
- Average cost per prescription
- $12.38
- Clinicians who prescribed it
- 160,530
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Hyclate Tablets and other antibacterial drugs, Doxycycline Hyclate Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nurse Practitioners 24.3%
- Family Medicine 18.4%
- Physician Assistants 14.7%
- Internal Medicine 12.7%
- Dermatology 8.0%
- Emergency Medicine 3.6%
- Podiatrists 2.2%
- Infectious Disease 1.9%
- Pulmonology 1.8%
- Ophthalmology 1.8%
- Mohs Surgery 1.7%
- ENT (Otolaryngology) 0.9%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 40% from 2019 to 2024.
Biggest change by state since 2019
- North Dakota +76%
- Utah +68%
- Colorado +64%
- Delaware +56%
- West Virginia +55%
- Massachusetts (smallest change) −5%
- Vermont (smallest change) +20%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Acella Pharmaceuticals, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | orange round tablet, 9 mm | 501 |
Chartwell Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | pink powder | |
| 50 mg | orange round tablet, 7 mm | CE 30 |
| 50 mg | white capsule, 17 mm | 2984 |
| 100 mg | orange round tablet, 9 mm | 3626 |
| 100 mg | blue capsule, 21 mm | 2985 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 9 mm | MP 573 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
6 recalls since 2020
- Sep 2025 · Acella Pharmaceuticals, LLC · Class II
Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications. - Apr 2022 · McKesson Medical-Surgical Inc. Corporate Office · Class II
cGMP deviations: Temperature abuse - May 2020 · The Harvard Drug Group · Class II
Failed Dissolution Specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out-of-specification result. - May 2020 · American Health PAckaging · Class II
Failed dissolution specification - dissolution results of 59% (spec. NLT 85%) at the 24 month time point (end of shelf life). - May 2020 · Pd-Rx Pharmaceuticals, Inc. · Class II
Failed dissolution specifications - May 2020 · West-Ward Columbus Inc · Class II
Failed dissolution specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out of specification result.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.